arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immunovant, Inc.

IMVT Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$39.25
Today
as of Sep 4, 16:50 ET
Last 30 days -2.10% Jul 27 → Sep 04
$37.99 $39.86 $41.73 $43.61 $45.48 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$39.44
High
$39.73
Low
$38.73
Volume
$754,322
Avg Vol
$2M
Mkt Cap
$9.2B
P/E (TTM)
—
Beta
—
52w High
$45.42
52w Low
$14.58
Div Yield
—
Shares Out
$206M

Recent Press Releases & News last 60 days · 10 items

Aug 24 · 17:16 MT Newswires
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
Aug 24 · 14:09 MT Newswires
UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating
Aug 13 · 12:01 Motley Fool
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
▸ Show all 10 press releases & news Free account →

Overview

52-week range
$15
$45
80% of range
Avg surprise (last 3)
+0.8%
Avg reaction (last 2)
+20.4%
100% positive
Latest IV / EM
69%
EM ±10.8% · $39 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.76$-0.66$-0.56$-0.46$-0.36 Actual $-0.57Actual $-0.45Actual $-0.36Actual $-0.60Actual $-0.74Actual $-0.76Actual $-0.64Est $-0.72Actual $-0.60Est $-0.69Actual $-0.73Actual $-0.61Actual $-0.73Est $-0.60Actual $-0.75 JunSepDecJunSepDecMar/2025Jun/2025SepDecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-153M$-144M$-134M$-124M$-115M Sep 24Dec 24Jun 25Sep 25Dec 25Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.75 — — — — financials
Wed May 20, 2026Mar/2026 $-0.73 $-0.60 -21.7% -14.1% +35.3% earnings
Wed Dec 31, 2025Dec 2025 $-0.61 — — — — financials
Tue Sep 30, 2025Sep 2025 $-0.73 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.60 $-0.69 +13.0% — — earnings
Thu May 29, 2025Mar/2025 $-0.64 $-0.72 +11.1% — +5.6% earnings
Tue Dec 31, 2024Dec 2024 $-0.76 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.74 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.36 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.57 — — — — financials
Sat Dec 31, 2022Dec 2022 $-0.49 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income————————
Net income$-153M—$-111M$-127M$-121M—$-111M$-109M
EPS (diluted)$-0.75—$-0.61$-0.73$-0.71—$-0.76$-0.74

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$798M$902M$995M$522M$599M$714M$375M$473M
Inventory————————
Total current assets$851M$949M$1.04B$574M$652M$768M$413M$507M
Total assets$852M$957M$1.05B$583M$661M$776M$421M$516M
Long-term debt————————
Total liabilities$117M$104M$66M$63M$53M$69M$68M$67M
Total equity$735M$853M$986M$520M$609M$707M$353M$449M

Implied volatility — last 90 days

44%58%73%87%102% Jun 07 — IV 73% · EM ±10.0%Jun 08 — IV 81% · EM ±10.6%Jun 09 — IV 62% · EM ±7.8%Jun 10 — IV 69% · EM ±8.2%Jun 11 — IV 79% · EM ±8.7%Jun 12 — IV 60% · EM ±6.1%Jun 15 — IV 80% · EM ±5.8%Jun 19 — IV 49% · EM ±10.8%Jun 22 — IV 65% · EM ±13.5%Jun 23 — IV 64% · EM ±13.2%Jun 24 — IV 64% · EM ±12.8%Jun 25 — IV 65% · EM ±12.8%Jun 26 — IV 62% · EM ±11.8%Jun 29 — IV 65% · EM ±11.5%Jun 30 — IV 49% · EM ±8.4%Jul 01 — IV 45% · EM ±7.5%Jul 02 — IV 50% · EM ±8.1%Jul 03 — IV 52% · EM ±8.1%Jul 06 — IV 52% · EM ±7.3%Jul 07 — IV 51% · EM ±6.8%Jul 08 — IV 47% · EM ±5.8%Jul 09 — IV 71% · EM ±8.4%Jul 13 — IV 97% · EM ±8.1%Jul 15 — IV 45% · EM ±2.6%Jul 20 — IV 80% · EM ±18.9%Jul 21 — IV 83% · EM ±19.3%Jul 22 — IV 74% · EM ±16.8%Jul 23 — IV 69% · EM ±15.5%Jul 24 — IV 72% · EM ±16.0%Jul 27 — IV 79% · EM ±16.5%Jul 28 — IV 72% · EM ±14.7%Jul 29 — IV 85% · EM ±17.0%Jul 30 — IV 79% · EM ±15.4%Jul 31 — IV 79% · EM ±15.1%Aug 03 — IV 85% · EM ±15.1%Aug 04 — IV 63% · EM ±10.8%Aug 05 — IV 76% · EM ±12.7%Aug 06 — IV 72% · EM ±11.6%Aug 07 — IV 62% · EM ±9.8%Aug 10 — IV 62% · EM ±8.6%Aug 11 — IV 64% · EM ±8.4%Aug 12 — IV 81% · EM ±10.1%Aug 13 — IV 64% · EM ±7.5%Aug 14 — IV 60% · EM ±6.6%Aug 17 — IV 85% · EM ±7.1%Aug 18 — IV 102% · EM ±7.4%Aug 19 — IV 68% · EM ±4.0%Aug 24 — IV 76% · EM ±15.8%Aug 25 — IV 69% · EM ±14.1%Aug 26 — IV 69% · EM ±13.8%Aug 27 — IV 66% · EM ±13.0%Aug 28 — IV 68% · EM ±13.0%Aug 31 — IV 74% · EM ±13.1%Sep 01 — IV 73% · EM ±12.5%Sep 02 — IV 83% · EM ±13.9%Sep 03 — IV 65% · EM ±10.5%Sep 04 — IV 69% · EM ±10.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in